The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear.
Although most randomized controlled trials have shown negative results, uncontrolled studies …

Background Some observational studies have reported that transfusion of red-cell units that
have been stored for more than 2 to 3 weeks is associated with serious, even fatal, adverse …

Patients with cancer may be at increased risk of severe coronavirus disease 2019 (COVID-19),
but the role of viral load on this risk is unknown. We measured SARS-CoV-2 viral load …

Importance Accumulating evidence suggests that children infected with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) are more likely to manifest mild symptoms and …

In less than nine months, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
killed over a million people, including >25,000 in New York City (NYC) alone. The …

The World Health Organization (WHO) has declared coronavirus disease 2019 (COVID-19),
the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), …

The approved Pfizer and Moderna mRNA vaccines are well known to induce serum antibody
responses to the SARS-CoV-2 Spike (S)-protein. However, their abilities to elicit mucosal …

High-dose granulocyte transfusion therapy has been available for 20 years, yet its clinical
efficacy has never been conclusively demonstrated. We report here the results of RING (…

The emergence and spread of SARS-CoV-2 lineage B.1.1.7, first detected in the United
Kingdom, has become a global public health concern because of its increased transmissibility. …

Importance Increasing evidence supports the role of red blood cells (RBCs) in physiological
hemostasis and pathologic thrombosis. Red blood cells are commonly transfused in the …